Characterization of a Novel Oral Small Molecule PTH1R Agonist: Proof of Concept for an Alternative to Injectable Peptide-based Therapy for Hypoparathyroidism - Septerna

06.03.24

Publication

Up Next

View All

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

No results found.